KIF1A

FEBRUARY 18, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. Read the Article The post #ScienceSaturday: February 17, 2024 appeared first on KIF1A.

Therapies 52

Therapies DNA Clinical Trials Trials 52

Drug Target Review

JANUARY 24, 2024

Scientists from Northwestern Medicine have demonstrated that RNA interference could have a crucial role in the onset and development of Alzheimer’s disease (AD). Alzheimer’s disease Alzheimer’s is the most common cause of dementia. 15, 264 (2024). Alzheimer’s disease. 2006 July 29 [2024 January 18]; 368(9533):387-403.

RNA 63

RNA Disease DNA Engineering 63

Broad Institute

OCTOBER 4, 2023

Related links Merkin Prize Inaugural Merkin Prize in Biomedical Technology awarded to Dr. Marvin Caruthers for developing technology that efficiently synthesizes DNA The inaugural Richard N. Nominations for the 2024 Merkin Prize opened on September 6, 2023 and close on December 6, 2023 at 11:59 pm ET.

DNA 52

DNA RNA Science Protein Expression 52

Drug Discovery World

MARCH 18, 2024

Landmark genetic research could allow doctors to accurately predict whether a patient is at risk of developing common diseases, decades before any symptoms would become evident. Dr Yengo joins Professor Lara Malins from the Australian National University as 2024 Snow Fellows.

Research 130

Research DNA Doctors Disease 130

Drug Discovery World

OCTOBER 2, 2023

The goal is to generate DNA-encoded library (DEL) screening data for large numbers of under-addressed proteins in the human proteome – ultimately allowing drug discovery and machine learning (ML) experts from around the world to use the data to unlock disease targets of the future.

DNA 130

DNA Disease Science Research 130

Fierce BioTech

MAY 30, 2024

Quantify Cancer With Methylation-Based ctDNA Detection Download this resource to accelerate your oncology clinical trials, optimize patient enrollment, and monitor minimal residual disease and molecular response effectively.

Clinical Trials 52

Clinical Trials DNA Trials Therapies 52

Drug Discovery World

JUNE 7, 2023

Hosted by DDW and sponsored by DNA Script, join us for this free-to-attend roundtable to learn about the biggest opportunities for the future of drug discovery and development. Panellists will discuss the following questions: Where will the opportunities be in 2024? What can we expect from the cell & gene therapy market?

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Discovery World

JUNE 27, 2023

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Panelists will discuss the following questions: Where will the opportunities be in 2024? How important will mRNA-based vaccines be in treating viruses and diseases such as cancer?

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Discovery World

JUNE 22, 2023

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Panelists will discuss the following questions: Where will the opportunities be in 2024? How important will mRNA-based vaccines be in treating viruses and diseases such as cancer?

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Discovery World

JUNE 15, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Panelists will discuss the following questions: Where will the opportunities be in 2024? How important will mRNA-based vaccines be in treating viruses and diseases such as cancer?

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Discovery World

JUNE 8, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Panelists will discuss the following questions: Where will the opportunities be in 2024? How important will mRNA-based vaccines be in treating viruses and diseases such as cancer?

DNA 130

DNA Drugs Clinical Trials Vaccine 130

Drug Discovery World

APRIL 17, 2024

CAMP4 is exploiting these regulatory interactions to specifically control the expression of genes tied to disease. For many diseases, only small increases in expression are needed to make the difference between sickness and health. What diseases are you currently targeting? Can you give some examples?

Science 147

Science RNA Disease Protein Expression 147

PLOS: DNA Science

MARCH 28, 2024

A new drug has entered the arsenal against Duchenne muscular dystrophy (DMD), a genetic disease that affects boys and is challenging to treat. Results from the study that led to the FDA approval appeared in The Lancet Neurology in April 2024 with commentary. million DNA bases. Muscle makes up about 40 percent of body weight.

FDA Approval 75

FDA Approval Treatment FDA DNA 75

Drug Discovery World

FEBRUARY 7, 2024

His academic lab is technology-driven and focuses on developing and applying proteomic technologies to the study of underlying disease mechanisms, as well as the identification of diagnostic and prognostic markers across several different disease areas. Access the full podcast episode.

FDA Approval 147

FDA Approval Disease DNA FDA 147

Broad Institute

FEBRUARY 27, 2024

Broad-MIT Seminars in Chemical Biology By Rose Circeo February 27, 2024 Breadcrumb Home Research Broad-MIT Seminars in Chemical Biology MIT Chemistry and the Broad Institute host monthly seminars in chemical biology with the intent to hear from the thought-leaders and bring together chemical biologists from both academia and industry in the Boston/Cambridge (..)

RNA 52

RNA DNA Regulations Disease 52

Drug Target Review

APRIL 25, 2024

Generating epigenetic data to assess the effects of smoking on DNA methylation (DNAm) discovered several new regions associated with smoking. Characterising them can give us a better understanding of disease relevance and risk.” 2017 August 1 [2024 April 11]; 26(15):3014-3027. 2023 March 11 [2024 April 9]; 12(6):879.

DNA 63

DNA Disease Science Research 63

Drug Target Review

JANUARY 26, 2024

To find a DNA fragment that contained the intact ACE2 gene, complete with its embedded regulatory information, they searched libraries of cloned DNA fragments generated as part of the Human Genome Project. 2020 March 30 [2024 January 22]; 581:215-220. This study was published in Virology. Reference 1 Fan S, Ge J, Lan J, et al.

Production 113

Production DNA Virus Protein Expression 113

Broad Institute

MARCH 8, 2024

By Claire Hendershot March 8, 2024 Credit: National Institute of Allergy and Infectious Diseases, National Institutes of Health via U.S. There are a lot of patients that they couldn’t treat unless it was malaria or a small host of other diseases.

Research 112

Research Disease Medical Schools RNA 112

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. CHARMs are an elegant solution to the problem of silencing disease genes, and they have the potential to have an important position in the future of genetic medicines.”

Disease 142

Disease Therapies Engineering Clinical Trials 142

Broad Institute

FEBRUARY 27, 2024

CBTS Supergroup Meetings By Rose Circeo February 27, 2024 Breadcrumb Home Chembio-Therapeutics CBTS Supergroup Meetings Regular program meetings draw participants from many research communities to share cutting-edge research and brainstorm new project ideas in a wide variety of fields relevant to chemical biology and therapeutics science.

Targeted Protein Degradation 52

Targeted Protein Degradation DNA Engineering Science 52

Drug Discovery World

FEBRUARY 6, 2024

Auransa, which harnesses available data to discover highly intractable diseases with poorly understood biology. Pharos iBio, which utilises AI technology to develop treatments for refractory and rare diseases such as cancers and repurpose existing therapies.

Marketing 173

Marketing Laboratories Engineering Clinical Trials 173

LifeSciVC

APRIL 26, 2024

According to the latest Pitchbook data, venture creation in biotech hit its slowest quarterly pace in eight years during 1Q 2024. Beyond simply backing great science (separating the wheat from the chafe), setting a company up properly is critical, and early choices can get locked into the DNA of the company.

DNA 111

DNA Science Marketing Clinical Trials 111

Drug Discovery World

JANUARY 21, 2024

Most drugs under development today are designed to do the same thing: inhibit the function of proteins that contribute to disease. But this strategy misses a vast therapeutic opportunity: addressing the many diseases that are caused by insufficient levels or impaired function of otherwise beneficial proteins,” Bushell explains. “By

Vaccine 130

Vaccine Computational Chemistry Animal Testing Engineering 130

Drug Discovery World

FEBRUARY 28, 2024

Using a technique they’ve dubbed ‘cancer shredding’, the researchers at Gladstone Institutes, California, programmed CRISPR to zero-in on repeating DNA sequences present only in recurrent tumour cells – and then obliterate those cells by snipping away at them. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Target Review

FEBRUARY 16, 2024

Most of those with disease relapse had a lower IGR burden. This may be explained by the damage of DNA which induces structural rearrangements of the genome following platinum exposure. Internet] 2023 January 25 [2024 February 14]; 23(1):56-60. Internet] 2023 February [2024 February 15]; 182. Clinical Medicine Journal.

Clinical Trials 105

Clinical Trials DNA Treatment Trials 105

PLOS: DNA Science

APRIL 18, 2024

Clues to combatting a devastating disease can come from identifying people who have gene variants – mutations – that protect them, by slowing the illness or lowering the risk that it develops in the first place. That’s what the researchers wanted to find out, publishing their findings in the January 2024 Cell.

Disease 73

Disease Research DNA Therapies 73

Drug Discovery World

FEBRUARY 14, 2024

While a typical chemisty, manufacturing and controls (CMC) timeline from DNA to Investigational New Drug (IND) application in 2015 would have been approximately 24 months, by 2023 the same pathway was expected to take only 10 months. This means that they cannot cause disease and they generally do not need to be frozen for storage.

Vaccine 147

Vaccine Production Virus DNA 147

Drug Target Review

JANUARY 22, 2024

Pioneer TFs can recognise their target DNA sequences in compacted heterochromatin and can trigger remodelling of the adjoining chromatin landscape to provide accessibility to nonpioneer TFs. 2018 September [2024 January 15]; 293(36):13795-804. 2016 April [2024 January 15]; 37:76-81. Journal of Biological Chemistry.

DNA 58

DNA Engineering Hospitals Research 58

The Pharma Data

FEBRUARY 22, 2022

State-of-the-art facility will headquarter research efforts in Boston and New York to accelerate the development of RNA and DNA-based medicines. Occupancy of the new site is scheduled for 2024. Adams, vice president of genetic medicine at Lilly and co-director of the Institute. ” The Institute will be headquartered in 334,000 sq.

RNA 52

RNA DNA Disease Therapies 52

Broad Institute

JUNE 11, 2024

#WhyIScience Q&A: A biochemist uses mass spectrometry to find proteins involved in cancer By Corie Lok June 11, 2024 Breadcrumb Home #WhyIScience Q&A: A biochemist uses mass spectrometry to find proteins involved in cancer Moe Haines talks about how his open-minded approach to science led him to pursue a career in proteomics.

Science 106

Science Pharmacy DNA Pharmaceutical Companies 106

Broad Institute

FEBRUARY 29, 2024

By Leah Eisenstadt February 29, 2024 Credit: Courtesy of (clockwise, from top left) National Park Service; Rainer Zenz, Creative Commons license; Len Charnoff/Flickr, public domain; Riki7, public domain; National Park Service; Rufus46, Creative Commons. 27, 2024. Paper cited Schwartzman J, et al. 121 (10) e2310852121.

Hospitals 116

Hospitals Medical Schools International Research 116

KIF1A

APRIL 6, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. When a mutation causes a deletion or duplication of larger areas of DNA, we call it Copy Number Variation.

DNA 111

DNA Medical Schools Therapies Research 111

Broad Institute

MARCH 25, 2024

By Leah Eisenstadt March 25, 2024 Credit: Allison Colorado, Broad Communications Alex Navarro, Senior Program Coordinator for the Broad Biomedical Post-baccalaureate Scholars Program Alex Navarro didn’t always aspire to a career in science. During college, I studied microbiology and developed an interest in infectious disease.

Science 112

Science Cell Biology Research DNA 112

Agency IQ

MARCH 29, 2024

FDA’s oncology advisory committee to consider MRD as a multiple myeloma endpoint Yesterday, the FDA announced that its Oncologic Drugs Advisory Committee would weigh in on the potential use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials. immune cells and other blood cell types) lack.

FDA 40

FDA Clinical Trials Trials Treatment 40

KIF1A

JANUARY 13, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. As one cell turns into two, its DNA must be replicated and then pulled apart, so that when the cell divides each has all the DNA it needs to function.

DNA 105

DNA Regulations Drug Development FDA 105

KIF1A

JANUARY 20, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. Instead, this is what is called a splicing mutation; it occurs at the boundary between coding DNA that is read into RNA and protein, and noncoding DNA that is excluded.

DNA 105

DNA RNA Disease Research 105

The Pharma Data

JUNE 24, 2021

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).

DNA 52

DNA Clinical Trials Trials Biosimilars 52